NEMLUVIO shows sustained benefits in atopic dermatitis for up to three years

NEMLUVIO shows sustained benefits in atopic dermatitis for up to three years

Galderma has presented new long-term data on NEMLUVIO for the treatment of atopic dermatitis.

Atopic dermatitis is a chronic skin condition that can cause inflammation, redness, dryness and severe itching.

The study followed patients aged 12 years and older. Among those who responded well by Week 16, most maintained their improvements for up to three years.

By Week 152:

🔹 76% had clear or almost clear skin;

🔹 80% achieved at least a 90% improvement in disease severity;

🔹 50% achieved complete skin clearance;

🔹 80% were itch-free or nearly itch-free.

In the broader study population, improvements in skin symptoms, itching and quality of life were also sustained over the long term.

Positive results were also reported in children aged 2–11 years through Week 52.

No new safety signals were identified during long-term follow-up.